Screener
MapLight Therapeutics, Inc. MPLT Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $53,684 | $19,787 |
| General and administrative | 10,819 | 3,756 |
| Total operating expenses | 64,503 | 23,543 |
| Loss from operations | (64,503) | (23,543) |
| Other income, net: | ||
| Interest income | 2,472 | 811 |
| Other income, net | 1,363 | 392 |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s total operating expenses?
- MapLight Therapeutics, Inc. (MPLT) reported total operating expenses of $64.5M in Q1 2026.
- How has MapLight Therapeutics, Inc.'s total operating expenses changed year-over-year?
- MapLight Therapeutics, Inc.'s total operating expenses increased by 174.0% year-over-year, from $23.54M to $64.5M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about MapLight Therapeutics, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude